Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
Fecha
2020-06-12Autor
Machiels, Julian D
Bleeker-Rovers, Chantal P
Heine, Rob ter
Rahamat-Langendoen, Janette
de Mast, Quirijn
Oever, Jaap ten
Bousema, Teun
van Crevel, Reinout
Wertheim, Heiman FL
Documentos PDF
Resumen en idioma extranjero
The severity of COVID-19 has resulted in a global rush to find the right antiviral treatment to conquer the pandemic and to treat patients. This requires reliable studies to support treatment. In a recently published study by Gautret et al. the authors concluded that hydroxychloroquine monotherapy and hydroxychloroquine in combination with azithromycin reduced viral load. However, this trial has several major methodological issues, including the design, outcome measure and the statistical analyses. In this paper we discuss the background, clinical evidence, pharmacology and methodological issues related to this clinical trial. We understand the rush to release results, however in case conclusions are far reaching the evidence needs to be robust.
Palabras clave
(Hydroxy)chloroquine; 2019-nCoV; AzithromycinEnlace al recurso
https://www.sciencedirect.com/science/article/pii/S0924857920302260?via%3Dihub#abs0002Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.